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Nutrition regulates energy balance; however, dysfunction of energy balance can cause
metabolic disorders, such as obesity and diabetes. Fatty acids are an essential energy
source and signaling molecules that regulate various cellular processes and physiological
functions. Recently, several orphan G protein-coupled receptors were identified as free
fatty acid receptors (FFARs). GPR40/FFAR1 and GPR120/FFAR4 are activated by medium-
and/or long-chain fatty acids, whereas GPR41/FFAR3 and GPR43/FFAR2 are activated by
short-chain fatty acids. FFARs are regarded as targets for novel drugs to treat metabolic
disorders, such as obesity and type 2 diabetes, because recent studies have showed
that these receptors are involved in the energy metabolism in various tissues, including
adipose, intestinal, and immune tissue. In this review, we summarize physiological roles of
the FFARs, provide a comprehensive overview of energy regulation by FFARs, and discuss
new prospects for treatment of metabolic disorders.
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INTRODUCTION
Poor dietary habits are a major risk factor for metabolic syn-
drome. Shifting to a diet low in carbohydrate and high in fat can
causes the accumulation of excess energy leading to metabolic
disorders, such as obesity, hyperlipidemia, and type 2 diabetes
(Kahn et al., 2006; Sanz et al., 2010). In addition to glucose and
amino acids, fatty acids derived from dietary fat are an essential
energy source for life. Recently, a series of orphan G protein-
coupled receptors (GPCRs) were determined to be free fatty acid
receptors (FFARs), suggesting that free fatty acids (FFAs) are both
energy source and signaling molecules (Hara et al., 2013). These
receptors are now regarded as targets for novel drugs for the
treatment of metabolic syndromes because they are activated by
FFAs. In this review, we summarize the current understanding of
the physiological roles of FFARs in energy metabolism and discuss
their potential as therapeutic targets for the treatment of obesity
and diabetes.
FATTY ACIDS AND FFAR FAMILY
Fatty acids are categorized by carbon chains length. Short-chain
fatty acids (SCFAs) contain fewer than 6 carbons, medium-
chain fatty acids (MCFAs) have 6–12 carbons, and long-chain
fatty acids (LCFAs) contain more than 12 carbons. Fatty acids are
an important energy source and are supplied primarily through
food intake, biosynthesis, and lipolysis from adipose tissues. For
example, the human body cannot generate α-linolenic acid C18:3
(n-3) and linoleic acid C18:2 (n-6), which have more than two
double bonds in their structures. Thus, ω-3 and ω-6 fatty acids
must be obtained through the diet to facilitate synthesis. MCFAs
and LCFAs are metabolized by β-oxidation, and are utilized as an
energy source in various tissues. SCFAs, such as acetate, propi-
onate, and butyrate, are produced via gut microbial fermentation
of indigestible polysaccharides, including dietary fiber, and are
utilized as energy sources by intestinal epithelial cells and liver.
Recently, it was reported that fatty acids act as both energy
sources and as signaling molecules. GPCRs that are activated by
FFAs are categorized according to ligand profile, depending on
the length of the FFA carbon chain. MCFAs and LCFAs activate
FFAR1 and FFAR4, whereas SCFAs activate FFAR3 and FFAR2
(Figure 1; Offermanns, 2014).
GPR40/FFAR1
FFAR1 is a receptor for MCFAs and LCFAs. Various FFAs acti-
vate FFAR1 in the micromolar concentration range, although
eicosatrienoic acid C20:3 (n-3) is the most potent agonist of
FFAR1 (Itoh et al., 2003). Itoh et al. (2003) reported that LCFAs
promote glucose-stimulated insulin secretion (GSIS) in pancre-
atic β cells. In this report, it was shown that FFAR1 is expressed in
pancreatic β cells, and that the specific and acute effects of FFAs on
pancreatic β cells were significantly decreased following the loss
of FFAR1 function (Itoh et al., 2003). In addition, Steneberg et al.
(2005) demonstrated that both the acute and chronic effects of
FFAs on insulin secretion were due to activation of FFAR1 using
Ffar1 knockout (KO) mice and pancreatic β cell-specific Ffar1
transgenic (TG) mice. The chronic effects of FFAs on GSIS were
significantly decreased by loss of FFAR1 function. In contrast, TG
overexpression of the human FFAR1 gene in mouse pancreatic β
cells under the control of mouse insulin II promoter prevented
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FIGURE 1 | Continued
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FIGURE 1 | Continued
Affinity of fatty acids and representative selective agonists for free fatty
acid receptors (FFARs). Endogenous (upper panel) and selective [lower
panel: (i) TAK-875/fasiglifam (Srivastava et al., 2014), (ii) CpdA (Oh et al.,
2014), (iii) NCG-21 (Sun et al., 2010), (vi) trans-2-methylcrotonic acid, (v)
propiolic acid, (vi) angelic acid (Schmidt et al., 2011), (vii) compound 34
(Ulven, 2012; Bindels et al., 2013), (viii) MAG7703 phenylacetamide 1, (ix)
MAG7703 phenylacetamide 2 (Lee et al., 2008), (x) compound 1, (xi)
compound 2 (Hudson et al., 2013), (xii) 2-methylbutyric acid, (xiii)
1-methylcyclopropanecarboxylic acid, (xiv) cyclopropylacetic acid (Schmidt
et al., 2011), (xv) compound 4 (Leonard et al., 2006)] agonists for FFAR1,
FFAR2, FFAR3, and FFAR4.
the development of hyperglycemia in high fat diet (HFD)-fed
mice and improved insulin secretion and glucose tolerance in
genetically diabetic mice (Nagasumi et al., 2009). Kristinsson
et al. (2013) further showed that acute and chronic effects of
palmitate on insulin secretion were partly mediated by FFAR1.
FFAR1 agonists-induced GSIS was inhibited by the treatment
with FFAR1 antagonist. Additionally, long-term treatment with
palmitoleate decreased GSIS, and this effect was inhibited by
FFAR1 antagonist. Natalicchio et al. (2013) showed that expres-
sion of exendin-4 in pancreatic β cells inhibits FFAR1 expression
and phosphorylation of stress kinases, such as Jun N-terminal
kinase (JNK) and mitogen-activated protein kinase (MAPK),
which in turn could prevent the palmitoleate-induced apoptosis.
Furthermore, Meidute Abaraviciene et al. (2013) showed that
FFAR1 protein level in pancreatic islets are regulated by glucose
and FFAs, and are associated with insulin secretion. Repeated
administration of selective FFAR1 agonists increased insulin sen-
sitivity and improved glucose metabolism in vivo (Tanaka et al.,
2013). Thus, several factors, including the energy expenditure,
glucose metabolism, plasma FFA level, and expression levels of
FFAR1, contribute to the acute chronic effects of FFAs medi-
ated by FFAR1 in pancreatic β cells. FFAR1 is also expressed
in intestinal endocrine cells. Edfalk et al. (2008) reported that
FFAR1 was expressed in intestinal L and K cells, which secrete the
incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP) and in I cells, which
secrete cholecystokinin (Liou et al., 2011). Therefore, FFAR1
modulates FFA-induced insulin secretion from β cells directly
and indirectly, through the regulation of incretin secretion. Based
on this data, a selective FFAR1 agonist might be useful for the
treatment of type 2 diabetes. TAK-875, or fasiglifam, developed
by Takeda, is an orally available, potent, and selective partial-
agonist of FFAR1, which reached phase III clinical trials for the
treatment of type 2 diabetes (Srivastava et al., 2014). However,
Takeda recently discontinued the phase III trial because of liver
toxicity.
GPR120/FFAR4
FFAR4 was successfully deorphanized in 2005 and identified as
a receptor for MCFAs and LCFAs that promotes GLP-1 secre-
tion from the colon (Hirasawa et al., 2005). Various ω-3 or ω-
6 polyunsaturated fatty acids, including docosahexaenoic acid
(DHA) C22:6 (n-3) and EPA C20:5 (n-3), activate FFAR4 in the
micromolar concentration range. Among these FFAs, FFAR4 is
most potently activated by α-linolenic acid C18:3 (n-3) (Hirasawa
et al., 2005). Although its ligand profiles are similar to those of
FFAR1, the amino acid sequence identity between FFAR4 and
FFAR1 is only 10%. FFAR4 was shown to be widely expressed in
various tissue and cell types, including intestinal tissue, adipose
tissue, macrophages, and pancreas (Ichimura et al., 2009, 2012;
Oh et al., 2010). The diverse tissue distribution of FFAR4 suggests
that FFAR4 has multiple functions in the homeostatic regula-
tion of systemic metabolism and inflammation. FFAR4 is also
expressed in adipocytes, but was not detected in pre-adipocytes
(Gotoh et al., 2007; Ichimura et al., 2012). Furthermore, FFAR4
expression was increased by lipid accumulation in cells during the
induction of adipogenesis in 3T3-L1 cells (Gotoh et al., 2007).
Both knockdown of Ffar4 by siRNA in 3T3-L1 cells and gene
deficiency in mouse embryonic fibroblasts suppressed the expres-
sion of adipogenic genes and lipid accumulation (Gotoh et al.,
2007; Ichimura et al., 2012). These data indicated that FFAR4
may play an important role in the differentiation and maturation
of adipocytes. Ffar4 mRNA expression was increased in white
adipose tissue of HFD-fed mice (Gotoh et al., 2007). Recently, we
found and reported that gene deficiency and dysfunction of Ffar4
lead to obesity in both mice and humans (Ichimura et al., 2012).
We found that HFD-fed Ffar4 KO mice developed severe obesity,
which was accompanied by decreased differentiation and lipoge-
nesis in adipocytes. Furthermore, severe fatty liver, enhanced hep-
atic lipogenesis, increased fasting glucose, and impaired responses
to insulin and glucose tolerance were observed in HFD-fed Ffar4
KO mice. We reported two non-synonymous mutations, p.R270H
and p.R67C, by exon sequencing of FFAR4 in obese and lean
European subjects. Subsequent in vitro experiments revealed that
the p.R270H mutant, which was significantly associated with
obesity, lacked the ability to transduce LCFA signals unlike the
p.R67C mutant, which was not associated with obesity. Taken
together, the studies of humans lacking functional FFAR4 and
Ffar4 KO mice indicate that dysfunction of FFAR4 leads to obesity
in both mice and humans (Ichimura et al., 2012).
Oh and Olefsky (2012) demonstrated that FFAR4 activa-
tion exerts anti-inflammatory effects on macrophages. FFAR4
regulates DHA-modulated, lipopolysaccharide (LPS)-induced
cyclooxygenase-2 in macrophages through β-arrestin signaling.
Thus, FFAR4 is a functional ω-3 FFA receptor that mediates
potent insulin sensitizing and antidiabetic effects through sup-
pression of macrophage-induced tissue inflammation. Moreover,
Oh et al. (2014) recently reported an orally available small
molecule FFAR4 agonist. This selective agonist improved insulin
resistance and chronic inflammation in obese mice. Hence,
FFAR4 agonists could become future insulin-sensitizing agents
for the treatment of type 2 diabetes and other human insulin-
resistant states.
GPR41/FFAR3
FFAR3 is an SCFA receptor that can be activated by propionate
(C3), butyrate (C4), and valerate (C5) (Brown et al., 2003; Le
Poul et al., 2003). FFAR3 expression in intestinal L cells, which
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secrete peptides YY (PYY) and GLP-1, indicated that this recep-
tor is involved in energy homeostasis (Tazoe et al., 2009). PYY
and GLP-1 secretion was reduced in primary cultured endocrine
cells derived from Ffar3 KO mice (Samuel et al., 2008; Tolhurst
et al., 2012). After colonization of germ-free mice with spe-
cific microbes, wild type mice, but not Ffar3 KO mice, showed
an increase in PYY levels. Thus, PYY secretion from intestinal
L cells is regulated by gut microbes SCFAs acting on FFAR3.
We previously reported that Ffar3 was abundantly expressed in
sympathetic ganglia (Kimura et al., 2011). Our data indicated
that propionate-induced FFAR3 activation resulted in increased
heart rate and energy expenditure via sympathetic outflow.
Importantly, these effects were not exhibited in Ffar3 KO mice.
Moreover, sympathetic activation by FFAR3 directly promotes
noradrenalin release from sympathetic neurons (Inoue et al.,
2012). In contrast, under fasting conditions, FFAR3 contributed
to the suppression of energy expenditure. β-Hydroxybutyrate, a
ketone body produced in the liver during starvation, decreased
sympathetic outflow by antagonizing FFAR3 (Kimura et al., 2011;
Inoue et al., 2012). Thus, FFAR3 regulates sympathetic activity
by sensing the nutritional state, thereby maintaining body energy
homeostasis.
Recently, De Vadder et al. (2014) reported that FFAR3
improves insulin resistance via the gut–brain neural circuit,
through activation of peripheral nerve FFAR3 by SCFAs produced
from dietary fibers by gut microbes. Thus, FFAR3 agonists acting
on peripheral neurons may serve as a novel type of therapeu-
tic for metabolic disorders. Several synthetic compounds were
reported as FFAR3 agonists or antagonists and structural analysis
revealed that the presence of small carboxylic acids, including
cyclopropanecarboxylic acid, in the structure enhanced FFAR3
selectivity (Leonard et al., 2006). Moreover, Hudson et al. (2014)
recently reported these synthetic ligands are allosteric modulators
of FFAR3 with complex and diverse pharmacology.
GPR43/FFAR2
FFAR2 is also an SCFA receptor; however, the ligand affinity
differs between FFAR2 and FFAR3. Acetate and propionate acti-
vate FFAR2 with high potency, followed by butyrate and other
SCFAs (Brown et al., 2003; Le Poul et al., 2003). FFAR2 like
FFAR3 is expressed in L cells. SCFAs-induced FFAR2 activation
promotes GLP-1 secretion in mixed colonic primary cultures
and STC-1 cells (Tolhurst et al., 2012; Hudson et al., 2013).
Ffar2 KO mice exhibited reduced SCFA-induced GLP-1 secretion
FIGURE 2 | Physiological functions of free fatty acid receptors (FFARs). Medium- and long-chain fatty acids derived from dietary fat act as ligands for FFAR1
or FFAR4 (I). Short-chain fatty acids produced by gut microbes from indigestible dietary fiber act as ligands for FFAR3 or FFAR2 (II).
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both in vitro and in vivo and had impaired glucose tolerance.
FFAR2 was also abundantly expressed in adipose tissues. Hong
et al. (2005) showed that expression of Ffar2 was significantly
greater in white adipose tissues of mice with HFD-induced obesity
than in normal chow-fed mice. Further, they showed that SCFAs
suppressed isoproterenol-induced lipolysis in a concentration-
dependent manner in 3T3-L1-derived adipocytes (Hong et al.,
2005). Additionally, Ge et al. (2008) demonstrated that these
effects were dependent on FFAR2 using Ffar2 KO mice.
In a series of in vitro and in vivo studies using Ffar2 mutant
mice, we showed that SCFA-mediated FFAR2 activation sup-
pressed adipose insulin signaling, leading to inhibition of fat
accumulation in adipose tissue (Kimura et al., 2013). In this study,
we found that the source of FFAR2 ligands was dependent on
gut microbes, because Ffar2 deficiency induced obesity in mice,
whereas mice overexpressing Ffar2 only in adipose tissues exhib-
ited leanness under normal conditions. Neither of these mouse
strains exhibited either phenotype under germ-free conditions or
after antibiotic treatment. Based on this data, FFAR2 regulates
adipose insulin signaling by sensing SCFAs, provided by gut
microbes, thereby regulating fat accumulation and maintaining
body energy homeostasis. Thus, FFAR2 stimulation suppresses fat
accumulation in adipose tissue and promotes GLP-1 secretion in
gut, thereby improving insulin resistance. FFAR2 agonists could
be used as novel insulin-sensitizing drugs for the treatment of
type 2 diabetes.
Hence, recently, development of FFAR2 selective agonists or
antagonists to prevent its pathophysiological functions is pro-
gressing. Structure–activity relationship analysis revealed small
carboxylic acids at the orthosteric binding site where ligands with
substitute sp(2)-hybridized alpha-carbons showed selectivity for
FFAR2. In contrast, ligands with sp(3)-hybridized alpha-carbons
showed selectivity for FFAR3 (Schmidt et al., 2011). In addition,
several selective synthetic FFAR2 agonists have been reported,
including allosteric compounds (Lee et al., 2008) and orthos-
teric compounds (Hudson et al., 2013). Beside FFAR2 related
metabolic regulation, many studies have investigated the role of
FFAR2 in regulating inflammatory responses (Maslowski et al.,
2009; Offermanns, 2014). GLPG0974 developed by Galapagos, is
an orally available small FFAR2 inhibitor that reached phase II
clinical trials for the potential treatment of inflammatory bowel
disease. According to the company, the first exploratory phase II
clinical study in ulcerative colitis (ClinicalTrials.gov Identifier1:
NCT01829321) suggested that “GLPG0974 was safe and well
tolerated and showed two relevant biomarker effects.” However,
these biomarker reductions did not result in a clinical improve-
ment within 4 weeks2.
CONCLUSION
In recent years, many metabolic and immune response pathways
have been reported in relation to nutrient sensing systems. Several
studies have provided evidence that FFARs are dietary sensors
expressed in both metabolic tissues and immune cells that regu-
1http://www.clinicaltrials.gov/ct2/show/NCT01829321?term=GLPG0974
&rank=3
2http://www.glpg.com/index.php/randd/pipeline/glpg0974-inflammatory/
late both energy metabolism and inflammatory responses. These
investigations will lead to new insights in nutritional science and
drug discovery science, due to the importance of FFA signaling
in diverse metabolic process (Figure 2). Since the inflammatory
response is also related to the development of obesity and type 2
diabetes, the FFAR family is expected to be a potential therapeutic
target for the treatment of these diseases. Although the detailed
signaling mechanism and physiological functions of FFARs in
tissues are unclear, a further understanding of the regulation of
energy metabolism and inflammatory responses by the FFAR
family represents an important avenue of research in drug devel-
opment for the treatment of obesity and type 2 diabetes.
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